Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641.
- Sexual dysfunctions. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text revision. American Psychiatric Association; 2022:477-510.
Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003.
Allen MS, Wood AM, Sheffield D. The psychology of erectile dysfunction. Curr Dir Psychol Sci. 2023;32(6):487-493.
Geerkens MJM, Al-Itejawi HHM, Nieuwenhuijzen JA, et al. Sexual dysfunction and bother due to erectile dysfunction in the healthy elderly male population: prevalence from a systematic review. Eur Urol Focus. 2020;6(4):776-790.
Bravi CA, Tin A, Montorsi F, et al. Erectile function and sexual satisfaction: the importance of asking about sexual desire. J Sex Med. 2020;17(2):349-352.
Mostyn P, Morgan L. Are men with erectile dysfunction able to ejaculate?—a survey. J Forensic Leg Med. 2013;20(4):239-241.
- National Library of Medicine. Erection problems. MedlinePlus. https://medlineplus.gov/ency/article/007617.htm
Sheng Z. Psychological consequences of erectile dysfunction. Trends Urol Men’s Health. 2021;12(6):19-22.
Maestre-Lorén F, Castillo-Garayoa JA, López-I-Martín X, et al. Psychological distress in erectile dysfunction: the moderating role of attachment. Sex Med. 2021;9(5):100436.
Irwin GM. Erectile dysfunction. Prim Care. 2019;46(2):249-255.
Rew KT, Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician. 2016;94(10):820-827.
Diaz VA, Close JD. Male sexual dysfunction. Prim Care. 2010;37(3):473-489.
Corona G. Erectile dysfunction and premature ejaculation: a continuum movens supporting couple sexual dysfunction. J Endocrinol Invest. 2022;45(11):2029-2041.
Mulhall JP, Goldstein I, Bushmakin AG, et al. Validation of the erection hardness score. J Sex Med. 2007;4(6):1626-1634.
Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822-830.
Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319-326.
van Kollenburg RAA, de Bruin DM, Wijkstra H. Validation of the electronic version of the International Index of Erectile Function (IIEF-5 and IIEF-15): a crossover study. J Med Internet Res. 2019;21(7):e13490.
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432.
Al-Zubaidi M, Hawks C, Fernando S, et al. Relationship between lower urinary tract symptoms (LUTS) and prostate cancer: a persistent myth. J Clin Urol. 2023.
Petering RC, Brooks NA. Testosterone therapy: review of clinical applications. Am Fam Physician. 2017;96(7):441-449.
Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P&T. 2013;38(7):407-419.
Lee M. Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. Clin Ther. 2011;33(11):1590-1608.
Rajagopalan P, Mazzu A, Xia C, et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol. 2003;43(3):260-267.
Seftel AD. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol. 2004;27(4):I14-I19.
Zinner N. Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study. J Sex Med. 2007;4(1):137-144.
Bivalacqua TJ, Allen BK, Brock G, et al. Acute ischemic priapism: an AUA/SMSNA guideline. J Urol. 2021;206(5):1114-1121.
Bivalacqua TJ, Allen BK, Brock GB, et al. The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA/SMSNA guideline. J Urol. 2022;208(1):43-52.
Muneer A. Comparison of EAU and UK guidelines on priapism. J Clin Urol. 2018;11(2):127-131.
Shigehara K, Namiki M. Clinical management of priapism: a review. World J Mens Health. 2016;34(1):1-8.
Roghmann F, Becker A, Sammon JD, et al. Incidence of priapism in emergency departments in the United States. J Urol. 2013;190(4):1275-1280.
Hosny K, Nosseir M, Pearce I. Malignant priapism: review of the report in three decades. J Clin Urol. 2020;13(5):382-391.
Hudnall M, Reed-Maldonado AB, Lue TF. Advances in the understanding of priapism. Transl Androl Urol. 2017;6(2):199-206.
Asanad K, Halpern JA, Brannigan RE. What is priapism? JAMA. 2024;331(15):1340.
Ortaç M, Çevik G, Akdere H, et al. Anatomic and functional outcome following distal shunt and tunneling for treatment ischemic priapism: a single-center experience. J Sex Med. 2019;16(8):1290-1296.
Addar A, Al Fraidi O, Nazer A, et al. Priapism for 10 days in a patient with SARS-CoV-2 pneumonia: a case report. J Surg Case Rep. 2021;2021(4):rjab020.
Alnajjar HM, Muneer A. Recent advances in understanding and treating priapism. Fac Rev. 2022;11:23.
Bintoro SUY, Romadhon PZ, Suryantoro SD, et al. Case report: priapism as the clinical presenting feature of chronic myeloid leukemia: case report and 20-year literature review. F1000 Res. 2021;10:571.
Boucher-Hayes D, Nolan P, Pate G. Treatment-resistant priapism associated with long-term low-molecular-weight heparin. BMJ Case Rep. 2021;14(4):e241897.
Ericson C, Baird B, Broderick GA. Management of priapism: 2021 update. Urol Clin North Am. 2021;48(4):565-576.
James Johnson M, Hallerstrom M, Alnajjar HM, et al. Which patients with ischemic priapism require further investigation for malignancy? Int J Impot Res. 2020;32(2):195-200.
Karayagmurlu A, Coskun M. Successful management of methylphenidate or atomoxetine-related priapism during attention-deficit hyperactivity disorder treatment. J Clin Psychopharmacol. 2020;40(3):314-315.
Olson C, Jhawar A, Elfessi Z, et al. Hydroxyzine-induced priapism. Am J Emerg Med. 2021;48:375.e5-375.e6.
Tabei SS, Baas W, Brooks A, et al. Malignant priapism: case report and update on management protocols. Transl Androl Urol. 2023;12(10):1607-1613.
De Niro AJN, Duarsa GWK, Yudiana IW, et al. Predictors of priapism incidence and recurrence in sickle cell disease patients. Afr J Urol. 2023;29:45.
Rezaee ME, Gross MS. Are we overstating the risk of priapism with oral phosphodiesterase type 5 inhibitors? J Sex Med. 2020;17(8):1579-1582.
Alvey L, Tabei SS, Baas W. Treatment of obstructive sleep apnea relieves stuttering priapism in patient with sickle cell disease: a case report. Transl Androl Urol. 2024;13(7):1297-1301.
Joice GA, Liu JL, Burnett AL. Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm. BJU Int. 2021;127(5):498-506.
Manjunatha N, Benegal V. Stuttering priapism associated with topiramate. Gen Hosp Psychiatry. 2015;37(6):620.e1-620.e2.
Offenbacher J, Barbera A. Penile emergencies. Emerg Med Clin North Am. 2019;37(4):583-592.
Kousournas G, Muneer A, Ralph D, et al. Contemporary best practice in the evaluation and management of stuttering priapism. Ther Adv Urol. 2017;9(9-10):227-238.
Palka J, DuComb W, Begun E, et al. Factors associated with corporoglandular shunting for patients with first-time ischemic priapism. Urology. 2021;154:191-195.
Drake T, Rustom J, Davies M. Phimosis in childhood. BMJ. 2013;346:f3678.
Morris BJ, Matthews JG, Krieger JN. Prevalence of phimosis in males of all ages: systematic review. Urology. 2020;135:124-132.
Denniston GC, Hill G. Gairdner was wrong. Can Fam Physician. 2010;56(10):986-987.
McGregor TB, Pike JG, Leonard MP. Pathologic and physiologic phimosis: approach to the phimotic foreskin. Can Fam Physician. 2007;53(3):445-448.
Radmayr C, Bogaert G, Bujons A, et al.; EAU Guidelines on Paediatric Urology. https://uroweb.org/guidelines/paediatric-urology
Moreno G, Ramirez C, Corbalán J, et al. Topical corticosteroids for treating phimosis in boys. Cochrane Database Syst Rev. 2024(1):CD008973.
Nguyen ATM, Holland AJA. Balanitis xerotica obliterans: an update for clinicians. Eur J Pediatr. 2020;179(1):9-16.
Charlton OA, Smith SD. Balanitis xerotica obliterans: a review of diagnosis and management. Int J Dermatol. 2019;58(7):777-781.
Celis S, Reed F, Murphy F, et al. Balanitis xerotica obliterans in children and adolescents: a literature review and clinical series. J Pediatr Urol. 2014;10(1):34-39.
Bromage SJ, Crump A, Pearce I. Phimosis as a presenting feature of diabetes. BJU Int. 2008;101(3):338-340.
Sneppen I, Thorup J. Foreskin morbidity in uncircumcised males. Pediatrics. 2016;137(5):e20154340.
Czajkowski M, Czajkowska K, Zarańska K, et al. Male circumcision due to phimosis as the procedure that is not only relieving clinical symptoms of phimosis but also improves the quality of sexual life. Sex Med. 2021;9(2):100315.
Herzog LW, Alvarez SR. The frequency of foreskin problems in uncircumcised children. Am J Dis Child. 1986;140(3):254-256.
Porche DJ. Paraphimosis: an emergency condition. J Nurse Pract. 2006;2(8):606-607.
Palmisano F, Gadda F, Spinelli MG, et al. Glans penis necrosis following paraphimosis: a rare case with brief literature review. Urol Case Rep. 2017;16:57-58.
Abbas T, McCarthy L. Foreskin and penile problems in childhood. Surgery (Oxf). 2022;40(5):326-331.
Burstein B, Paquin R. Comparison of outcomes for pediatric paraphimosis reduction using topical anesthetic versus intravenous procedural sedation. Am J Emerg Med. 2017;35(10):1391-1395.
Vunda A, Lacroix LE, Schneider F, et al. Videos in clinical medicine. Reduction of paraphimosis in boys. N Engl J Med. 2013;368(13):e16.
Clifford ID, Craig SS, Nataraja RM, et al. Paediatric paraphimosis. Emerg Med Australas. 2016;28(1):96-99.
Pohlman GD, Phillips JM, Wilcox DT. Simple method of paraphimosis reduction revisited: point of technique and review of the literature. J Pediatr Urol. 2013;9(1):104-107.
Manjunath AS, Hofer MD. Urologic emergencies. Med Clin North Am. 2018;102(2):373-385.
Nehra A, Alterowitz R, Culkin DJ, et al.; American Urological Association Education and Research, Inc. Peyronie’s disease: AUA guideline. J Urol. 2015;194(3):745-753.
Patel DP, Christensen MB, Hotaling JM, et al. A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease. World J Urol. 2020;38(2):253-261.
Segundo A, Glina S. Prevalence, risk factors, and erectile dysfunction associated with Peyronie’s disease among men seeking urological care. Sex Med. 2020;8(2):230-236.
Al-Thakafi S, Al-Hathal N. Peyronie’s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl Androl Urol. 2016;5(3):280-289.
Brimley SC, Yafi FA, Greenberg J, et al. Review of management options for active-phase Peyronie’s disease. Sex Med Rev. 2019;7(2):329-337.
Pastuszak AW, Rodriguez KM, Solomon ZJ, et al. Increased risk of incident disease in men with Peyronie’s disease: analysis of U.S. claims data. J Sex Med. 2018;15(6):894-901.
Nugteren HM, Nijman JM, de Jong IJ, et al. The association between Peyronie’s and Dupuytren’s disease. Int J Impot Res. 2011;23(4):142-145.
de Jesús MR, Ramasamy R, Ibrahim E, et al. The use of ultrasonography in the evaluation and management of Peyronie’s disease. Urol Video J. 2020;7:100047.
Kozub A, Suleja A, Chłosta M, et al. Current trends in non-surgical management of Peyronie’s disease–a narrative review. Andrology. 2024;12(3):505-517.